Erschienen in:
08.10.2018 | Gastrointestinal Oncology
Outcomes of Non-curative Gastrectomy for Gastric Cancer: An Analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP)
verfasst von:
Yunni Jeong, MD, Alyson L. Mahar, PhD, Natalie G. Coburn, MD, MPH, Christopher J. Wallis, MD, MSC, Raj Satkunasivam, MD, MSc, Kaitlyn Beyfuss, MSc(c), Paul J. Karanicolas, MD, PhD, Calvin H. L. Law, MD, MPH, Julie Hallet, MD, MSc
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 13/2018
Einloggen, um Zugang zu erhalten
Abstract
Background
The surgical care of patients with metastatic gastric cancer (GC) remains debated. Despite level 1 evidence showing lack of survival benefit, surgery may be used for symptoms prevention or palliation. This study examined short-term postoperative outcomes of non-curative gastrectomy performed for metastatic GC.
Methods
A multi-institutional retrospective cohort study was conducted using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) registry, including gastrectomies for GC (2007–2015). The primary outcome was 30-day major morbidity. Multivariable analysis examined the association between metastatic status and outcomes adjusted for relevant demographic and clinical covariates.
Results
Of 5341 patients, 377 (7.1%) had metastases. Major morbidity was more common with metastases (29.4 vs. 19.6%; p < 0.001), driven by a higher rate of respiratory events. Prolonged hospital length of stay (beyond the 75th percentile: 11 days) was more likely with metastases than with no metastases (41.9 vs. 28.3%; p < 0.001). After adjustment, metastatic status was associated with major morbidity (odds ratio [OR], 1.49; 95% confidence interval [CI], 1.16–1.90). This association remained for respiratory events (OR, 1.58; 95% CI, 1.07–2.33), 30-day mortality (OR, 2.19; 95% CI, 1.38–3.48), and prolonged hospital stay (OR, 1.65; 95% CI, 1.31–2.07).
Conclusion
Non-curative gastrectomy for metastatic GC was associated with significant major morbidity and mortality as well as a prolonged hospital stay, longer than expected for gastrectomy for non-metastatic GC. These data can inform decision making regarding non-curative gastrectomy, helping surgeons to weigh the risks of morbidity against the potential benefits and alternative therapeutic options.